<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00327704</url>
  </required_header>
  <id_info>
    <org_study_id>LFB N°ALBU-0503</org_study_id>
    <nct_id>NCT00327704</nct_id>
  </id_info>
  <brief_title>Early Albumin Resuscitation During Septic Shock</brief_title>
  <official_title>Multicenter, Prospective, Randomized, Controlled Open Study Albumin 20% Versus Saline</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoire français de Fractionnement et de Biotechnologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoire français de Fractionnement et de Biotechnologies</source>
  <brief_summary>
    <textblock>
      Objective: To determine whether the early administration of albumin as an expander and
      antioxidant would improve survival on the 28th day for septic shock patients.

      Design: Prospective, multicenter, randomized, controlled versus saline, stratified on
      nosocomial infection and center.

      Setting: 27 Intensive Care Units (ICU) in France

      Coordinator: Pr J.P. Mira and Dr J. Charpentier - Cochin Hospital- Paris

      Patients: 800 patients could be included during the first 6 hours of their septic shock.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary outcome: Mortality during the 28 day period after randomization. The secondary
      outcomes: Evaluation of SOFA score, ventilator-free days, dialysis free days, catecholamine
      free days, days of hospitalisation, incidence of nosocomial infections.

      The albuminemia of all patients is requested before the treatment until Day 4 post treatment.

      The treatment is: Vialebex 20% 100ml every 8 hours during 3 days versus saline 100ml every 8
      hours during 3 days.

      The first patient will be in July 2006, the last patient expected is on July 2009.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality, any cause, during the 28 day period after randomization</measure>
    <time_frame>day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of sequential organ failure assessment (SOFA) score</measure>
    <time_frame>ICU period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>catecholamine free days</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of nosocomial infection</measure>
    <time_frame>ICU period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality at 90 days</measure>
    <time_frame>day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of ICU hospitalisation</measure>
    <time_frame>ICU discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of total hospitalisation</measure>
    <time_frame>hospital discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">794</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Albumin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albumin</intervention_name>
    <description>albumin 20% 100 ml/8 hours for 3 days</description>
    <arm_group_label>Albumin</arm_group_label>
    <other_name>Vialebex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>saline 100 ml/8hours for 3 days</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over 18 years old

          -  Septic shock &lt; 6 hours

          -  Agreement of patients

        Exclusion Criteria:

          -  Allergy to albumin

          -  Weight &gt; 120 kg

          -  Non septic shock

          -  Burned

          -  Cirrhosis

          -  Albumin perfusion 48 hours before randomization

          -  Pregnant women

          -  Cardiac dysfunction New York Heart Association (NYHA) 3 or 4

          -  Patients with therapeutic limitation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean P Mira, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Cochin Hospital, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julien Charpentier, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Cochin Hospital Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75 014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2006</study_first_submitted>
  <study_first_submitted_qc>May 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2006</study_first_posted>
  <last_update_submitted>April 5, 2011</last_update_submitted>
  <last_update_submitted_qc>April 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jean-Paul MIRA, Professor</name_title>
    <organization>Cochin Hospital, Paris France</organization>
  </responsible_party>
  <keyword>Septic Shock</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

